Larry A Allen,, Mhs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8397334/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Forecasting the Impact of Heart Failure in the United States. Circulation: Heart Failure, 2013, 6, 606-619.	3.9	2,206
2	Frailty Assessment in the Cardiovascular Care of Older Adults. Journal of the American College of Cardiology, 2014, 63, 747-762.	2.8	850
3	Decision Making in Advanced Heart Failure. Circulation, 2012, 125, 1928-1952.	1.6	678
4	Hospital Readmissions Reduction Program. Circulation, 2015, 131, 1796-1803.	1.6	475
5	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. JAMA Cardiology, 2018, 3, 44.	6.1	346
6	Validation and Potential Mechanisms of Red Cell Distribution Width as a Prognostic Marker in Heart Failure. Journal of Cardiac Failure, 2010, 16, 230-238.	1.7	344
7	Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2015, 21, 519-534.	1.7	283
8	2017 ACC Expert Consensus Decision Pathway for Optimization of HeartÂFailure Treatment: Answers to 10ÂPivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 71, 201-230.	2.8	235
9	Discharge to a Skilled Nursing Facility and Subsequent Clinical Outcomes Among Older Patients Hospitalized for Heart Failure. Circulation: Heart Failure, 2011, 4, 293-300.	3.9	165
10	Danon Disease. Circulation: Heart Failure, 2014, 7, 843-849.	3.9	162
11	Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBITâ€AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). Journal of the American Heart Association, 2018, 7, .	3.7	143
12	Clinical Outcomes After Continuous-Flow Left Ventricular Assist Device. Circulation: Heart Failure, 2014, 7, 1003-1013.	3.9	140
13	Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. American Heart Journal, 2014, 167, 601-609.e1.	2.7	135
14	Effectiveness of an Intervention Supporting Shared Decision Making for Destination Therapy Left Ventricular Assist Device. JAMA Internal Medicine, 2018, 178, 520.	5.1	132
15	Palliative care in patients with heart failure. BMJ, The, 2016, 353, i1010.	6.0	124
16	Effect of a Collaborative Care Intervention vs Usual Care on Health Status of Patients With Chronic Heart Failure. JAMA Internal Medicine, 2018, 178, 511.	5.1	123
17	Identifying Patients Hospitalized With Heart Failure at Risk for Unfavorable Future Quality of Life. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 389-398.	2.2	111
18	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation. JAMA Cardiology, 2018, 3, 1174.	6.1	111

#	Article	IF	CITATIONS
19	Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 168, 487-494.	2.7	107
20	Aging of the United States Population: Impact on Heart Failure. Current Heart Failure Reports, 2012, 9, 369-374.	3.3	94
21	Cardiac Calcitropes, Myotropes, andÂMitotropes. Journal of the American College of Cardiology, 2019, 73, 2345-2353.	2.8	93
22	End Points for Clinical Trials in Acute Heart Failure Syndromes. Journal of the American College of Cardiology, 2009, 53, 2248-2258.	2.8	92
23	Palliative Care and Hospice in Advanced Heart Failure. Progress in Cardiovascular Diseases, 2011, 54, 168-178.	3.1	91
24	Predictors and Prognostic Implications ofÂIncident Heart Failure in Patients WithÂPrevalent Atrial Fibrillation. JACC: Heart Failure, 2017, 5, 44-52.	4.1	91
25	An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 427-437.	1.6	88
26	Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation, 2015, 132, 1347-1353.	1.6	81
27	African Americans Are Less Likely to Receive Care by a Cardiologist During anÂIntensive Care Unit Admission for HeartÂFailure. JACC: Heart Failure, 2018, 6, 413-420.	4.1	81
28	Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. European Journal of Heart Failure, 2019, 21, 1064-1078.	7.1	79
29	Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary AtrialÂFibrillation Cohort. Journal of the American College of Cardiology, 2015, 65, 2691-2698.	2.8	76
30	Decision Making for Destination Therapy Left Ventricular Assist Devices. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 374-380.	2.2	74
31	Bereaved Caregiver Perspectives on the End-of-Life Experience of Patients With a Left Ventricular Assist Device. JAMA Internal Medicine, 2016, 176, 534.	5.1	72
32	Continuous Versus Bolus Dosing of Furosemide for Patients Hospitalized for Heart Failure. American Journal of Cardiology, 2010, 105, 1794-1797.	1.6	71
33	Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	71
34	Use of Risk Models to Predict Death in the Next Year Among Individual Ambulatory Patients With Heart Failure. JAMA Cardiology, 2017, 2, 435.	6.1	70
35	Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. Journal of Cardiac Failure, 2018, 24, 682-694.	1.7	70
36	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 314.	7.4	68

#	Article	IF	CITATIONS
37	Team-based Palliative and End-of-life Care for Heart Failure. Heart Failure Clinics, 2015, 11, 479-498.	2.1	65
38	Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. American Heart Journal, 2019, 211, 77-89.	2.7	64
39	Rates and Predictors of 30-Day Readmission Among Commercially Insured and Medicaid-Enrolled Patients Hospitalized With Systolic Heart Failure. Circulation: Heart Failure, 2012, 5, 672-679.	3.9	62
40	Patient factors associated with quality of life in atrial fibrillation. American Heart Journal, 2016, 182, 135-143.	2.7	62
41	The Affordable Care Act Medicaid Expansion Correlated With Increased Heart Transplant Listings in African-Americans But Not Hispanics orÂCaucasians. JACC: Heart Failure, 2017, 5, 136-147.	4.1	61
42	Ambulatory Inotrope Infusions in Advanced Heart Failure. JACC: Heart Failure, 2018, 6, 757-767.	4.1	59
43	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005358.	2.2	59
44	Who is susceptible to online health misinformation? A test of four psychosocial hypotheses Health Psychology, 2021, 40, 274-284.	1.6	59
45	Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity. Circulation: Heart Failure, 2018, 11, e005008.	3.9	58
46	Development of a Decision Aid for PatientsÂWith Advanced Heart Failure Considering a Destination Therapy LeftÂVentricular Assist Device. JACC: Heart Failure, 2015, 3, 965-976.	4.1	57
47	The Hospital Readmissions Reduction Program. JACC: Heart Failure, 2020, 8, 1-11.	4.1	57
48	A Multicenter Trial of a Shared Decision Support Intervention for Patients and Their Caregivers Offered Destination Therapy for Advanced Heart Failure: DECIDE-LVAD. Journal of Cardiovascular Nursing, 2016, 31, E8-E20.	1.1	54
49	How Medicine Has Changed the End of Life for Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2017, 70, 1276-1289.	2.8	52
50	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines–Heart Failure Registry. JAMA Cardiology, 2018, 3, 917.	6.1	50
51	Deactivation of Left Ventricular Assist Devices: Differing Perspectives of Cardiology and Hospice/Palliative Medicine Clinicians. Journal of Cardiac Failure, 2017, 23, 708-712.	1.7	49
52	The Perceptions of Important Elements of Caregiving for a Left Ventricular Assist Device Patient. Journal of Cardiovascular Nursing, 2016, 31, 215-225.	1.1	45
53	Psychosocial Evaluation of Candidates for Heart Transplant and Ventricular Assist Devices: Beyond the Current Consensus. Circulation: Heart Failure, 2019, 12, e006058.	3.9	45
54	Decision-Making for Destination Therapy Left Ventricular Assist Devices. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 172-178.	2.2	42

#	Article	IF	CITATIONS
55	Accuracy of physician prognosis in heart failure and lung cancer: Comparison between physician estimates and model predicted survival. Palliative Medicine, 2016, 30, 684-689.	3.1	41
56	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. Journal of Cardiac Failure, 2015, 21, 674-693.	1.7	39
57	Referral Criteria to Palliative Care for Patients With Heart Failure. Circulation: Heart Failure, 2020, 13, e006881.	3.9	38
58	Incidence and Predictors of Cognitive Decline in Patients with Left Ventricular Assist Devices. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 285-291.	2.2	37
59	Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Tj ETQq1 1 0.784	31 4. cgBT	/Oværlock 101
60	Discussing Outâ€ofâ€Pocket Costs With Patients: Shared Decision Making for Sacubitrilâ€Valsartan in Heart Failure. Journal of the American Heart Association, 2019, 8, e010635.	3.7	37
61	Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. Journal of Thrombosis and Thrombolysis, 2021, 52, 517-522.	2.1	36
62	Educational Resources for Patients Considering a Left Ventricular Assist Device. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 905-911.	2.2	33
63	Drug Layering in HeartÂFailure. JACC: Heart Failure, 2021, 9, 775-783.	4.1	32
64	Risk Factors for Adverse Outcomes by Left Ventricular Ejection Fraction in a Contemporary Heart Failure Population. Circulation: Heart Failure, 2013, 6, 635-646.	3.9	31
65	Acculturation and Outcomes Among Patients With Heart Failure. Circulation: Heart Failure, 2012, 5, 160-166.	3.9	30
66	The inpatient experience and predictors of length of stay for patients hospitalized with systolic heart failure: comparison by commercial, Medicaid, and Medicare payer type. Journal of Medical Economics, 2013, 16, 43-54.	2.1	30
67	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2021, 27, 826-836.	1.7	30
68	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	29
69	Multi-marker strategies in heart failure: clinical and statistical approaches. Heart Failure Reviews, 2010, 15, 343-349.	3.9	28
70	Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2014, 7, 251-260.	3.9	28
71	Caregivers of Patients Considering a Destination Therapy Left Ventricular Assist Device and a Shared Decision-Making Intervention. JACC: Heart Failure, 2018, 6, 904-913.	4.1	28
72	Bâ€Type Natriuretic Peptide Predicts 30â€Day Readmission for Heart Failure but not Readmission for Other Causes. Journal of the American Heart Association, 2014, 3, e000806.	3.7	27

#	Article	IF	CITATIONS
73	Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007612.	4.8	27
74	End of life for patients with left ventricular assist devices: Insights from INTERMACS. Journal of Heart and Lung Transplantation, 2019, 38, 374-381.	0.6	27
75	Disease understanding in patients newly diagnosed with atrial fibrillation. Heart, 2018, 104, 494-501.	2.9	25
76	Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19. Circulation: Heart Failure, 2021, 14, e008354.	3.9	25
77	Patient-Reported Outcomes in Heart Failure: Existing Measures and Future Uses. Current Heart Failure Reports, 2015, 12, 236-246.	3.3	24
78	Evidence of Cognitive Bias in Decision Making Around Implantable-Cardioverter Defibrillators: A Qualitative Framework Analysis. Journal of Cardiac Failure, 2017, 23, 794-799.	1.7	24
79	Medicare Mandates for Shared Decision Making in Cardiovascular Device Placement. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004899.	2.2	24
80	Rationale and study design of a patient-centered intervention to improve health status in chronic heart failure: The Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) randomized trial. Contemporary Clinical Trials, 2016, 51, 1-7.	1.8	22
81	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart, 2019, 105, heartjnl-2018-313642.	2.9	22
82	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. American Heart Journal, 2020, 220, 41-50.	2.7	22
83	Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. American Heart Journal, 2020, 223, 65-71.	2.7	22
84	Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) – Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. Journal of Cardiac Failure, 2022, 28, 1245-1254.	1.7	22
85	Perspectives from mechanical circulatory support coordinators on the pre-implantation decision process for destination therapy left ventricular assist devices. Heart and Lung: Journal of Acute and Critical Care, 2015, 44, 219-224.	1.6	20
86	Thinking Outside the Box: Treating Acute Heart Failure Outside the Hospital to Improve Care and Reduce Admissions. Journal of Cardiac Failure, 2015, 21, 667-673.	1.7	20
87	Palliative Inotrope Therapy. JAMA Cardiology, 2019, 4, 815.	6.1	20
88	Home Health Care Use and Post-Discharge Outcomes After HeartÂFailure Hospitalizations. JACC: Heart Failure, 2020, 8, 1038-1049.	4.1	20
89	Shared Decision Making in Cardiac Electrophysiology Procedures and Arrhythmia Management. Circulation: Arrhythmia and Electrophysiology, 2021, 14, CIRCEP121007958.	4.8	20
90	Skilled Nursing Facility Care for Patients With Heart Failure: Can We Make It "Heart Failure Ready?― Journal of Cardiac Failure, 2016, 22, 1004-1014.	1.7	19

#	Article	IF	CITATIONS
91	Changes in Care Delivery for Patients With Heart Failure During the COVID-19 Pandemic: Results of a Multicenter Survey. Journal of Cardiac Failure, 2020, 26, 635-636.	1.7	19
92	End Points for Comparative Effectiveness Research in Heart Failure. Heart Failure Clinics, 2013, 9, 15-28.	2.1	18
93	Patient Perspectives on Communication of Individualized Survival Estimates in Heart Failure. Journal of Cardiac Failure, 2017, 23, 272-277.	1.7	18
94	Relationship Between Anemia and Health Care Costs in Heart Failure. Journal of Cardiac Failure, 2009, 15, 843-849.	1.7	16
95	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 263-272.	4.0	16
96	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines – Heart Failure Program). American Journal of Cardiology, 2020, 125, 894-900.	1.6	15
97	Text Message Medication Adherence Reminders Automated and Delivered at Scale Across Two Institutions: Testing the Nudge System: Pilot Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007015.	2.2	15
98	The Complex Relationship of Race to Outcomes in Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2015, 128, 591-600.	1.5	14
99	Heart Failure Complicated by AtrialÂFibrillation. JACC: Heart Failure, 2017, 5, 107-109.	4.1	14
100	Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006255.	2.2	14
101	Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines–Heart Failure Hospitals. JAMA Cardiology, 2021, 6, 791.	6.1	14
102	Unique challenges of hospice for patients with heart failure: A qualitative study of hospice clinicians. American Heart Journal, 2015, 170, 524-530.e3.	2.7	13
103	Hashing It Out Over Cannabis. Circulation: Heart Failure, 2016, 9, .	3.9	13
104	Timing of Postdischarge Followâ€Up and Medication Adherence Among Patients With Heart Failure. Journal of the American Heart Association, 2018, 7, .	3.7	13
105	Show Me the Money. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007070.	2.2	13
106	Applying Clinical Decision Support Design Best Practices With the Practical Robust Implementation and Sustainability Model Versus Reliance on Commercially Available Clinical Decision Support Tools: Randomized Controlled Trial. JMIR Medical Informatics, 2021, 9, e24359.	2.6	13
107	Transitioning into a digital world: Time for providers to recommend internet health information?. American Heart Journal, 2015, 170, 1-2.	2.7	12
108	Chronic Norovirus Infections in Cardiac Transplant Patients. Progress in Transplantation, 2017, 27, 69-72.	0.7	12

#	Article	IF	CITATIONS
109	Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: insights from the NCDR PINNACLE® registry. BMC Cardiovascular Disorders, 2018, 18, 80.	1.7	12
110	Cause of Death in Patients With AcuteÂHeartÂFailure. JACC: Heart Failure, 2020, 8, 999-1008.	4.1	12
111	Use of Multiple Biomarkers in Heart Failure. Current Cardiology Reports, 2010, 12, 230-236.	2.9	11
112	Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. Circulation: Heart Failure, 2021, 14, e008548.	3.9	11
113	Patterns of beta-blocker intensification in ambulatory heart failure patients and short-term association with hospitalization. BMC Cardiovascular Disorders, 2012, 12, 43.	1.7	10
114	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal, 2019, 213, 81-90.	2.7	10
115	Decision Aid Implementation among Left Ventricular Assist Device Programs Participating in the DECIDE-LVAD Stepped-Wedge Trial. Medical Decision Making, 2020, 40, 289-301.	2.4	10
116	Content Analysis of Negative Online Reviews of Hospice Agencies in the United States. JAMA Network Open, 2020, 3, e1921130.	5.9	10
117	Hospice, She Yelped: Examining the Quantity and Quality of Decision Support Available to Patient and Families Considering Hospice. Journal of Pain and Symptom Management, 2017, 54, 916-921.e1.	1.2	9
118	Comorbidities and the decision to undergo or forego destination therapy left ventricular assist device implantation: An analysis from the Trial of a Shared Decision Support Intervention for Patients and their Caregivers Offered Destination Therapy for End-Stage Heart Failure (DECIDE-LVAD) study. American Heart Journal, 2019, 213, 91-96.	2.7	9
119	Can We Predict Who Will Be Alive and Well After Transcatheter Aortic Valve Replacement? Is That Useful to Individual Patients?. Circulation, 2014, 129, 2636-2637.	1.6	8
120	Exploring cognitive bias in destination therapy left ventricular assist device decision making: A retrospective qualitative framework analysis. American Heart Journal, 2016, 180, 64-73.	2.7	8
121	Atrial Fibrillation in Heart Failure US Ambulatory Cardiology Practices and the Potential for Uptake of Catheter Ablation: An National Cardiovascular Data Registry (NCDR ®) Research to Practice (R2P) Project. Journal of the American Heart Association, 2017, 6, .	3.7	8
122	Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal, 2020, 219, 21-30.	2.7	8
123	Patient Roadmaps for Chronic Illness: Introducing a New Approach for Fostering Patient-Centered Care. MDM Policy and Practice, 2021, 6, 238146832110199.	0.9	8
124	The influence of expected risks on decision making for destination therapy left ventricular assist device: An MTurk survey. Journal of Heart and Lung Transplantation, 2015, 34, 988-990.	0.6	7
125	Left Ventricular Assist Device Withdrawal: Ethical, Psychological, and Logistical Challenges. Journal of Palliative Medicine, 2020, 23, 456-458.	1.1	7
126	A multicenter trial of a shared DECision Support Intervention for Patients offered implantable Cardioverter-DEfibrillators: DECIDE-ICD rationale, design, Medicare changes, and pilot data. American Heart Journal, 2020, 226, 161-173.	2.7	7

#	Article	IF	CITATIONS
127	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008594.	3.9	7
128	Fulminant Myocarditis Following SARS-CoV-2 Infection. Journal of the American College of Cardiology, 2022, 79, 2144-2152.	2.8	7
129	Health System–Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. Journal of Cardiac Failure, 2022, , .	1.7	7
130	Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBITâ€AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. Journal of the American Heart Association, 2018, 7, .	3.7	6
131	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic. Circulation: Heart Failure, 2020, 13, e007456.	3.9	6
132	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007775.	4.8	6
133	Social Determinants of Health and Rates of Implantation for Patients Considering Destination Therapy Left Ventricular Assist Device. Journal of Cardiac Failure, 2021, 27, 497-500.	1.7	6
134	Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure. Journal of the American Heart Association, 2022, 11, .	3.7	6
135	Anchoring in Destination-Therapy Left Ventricular Assist Device Decision Making: A Mechanical Turk Survey. Journal of Cardiac Failure, 2016, 22, 908-912.	1.7	5
136	Organic Dissemination and Real-World Implementation of Patient Decision Aids for Left Ventricular Assist Device. MDM Policy and Practice, 2018, 3, 238146831876765.	0.9	5
137	"lt's Like a Death Sentence but It Really Isn't―What Patients and Families Want to Know About Hosp Care When Making End-of-Life Decisions. American Journal of Hospice and Palliative Medicine, 2020, 37, 721-727.	ice 1.4	5
138	An Electronically delivered, Patient-activation tool for Intensification of medications for Chronic Heart Failure with reduced ejection fraction: Rationale and design of the EPIC-HF trial. American Heart Journal, 2020, 229, 144-155.	2.7	5
139	Allergy and the Heart. JACC: Case Reports, 2020, 2, 1942-1946.	0.6	5
140	Systematizing Heart Failure Population Health. Heart Failure Clinics, 2020, 16, 457-466.	2.1	5
141	Perceived Stress and Depressive Symptoms as Predictors of Decisional Conflict in Dyads Considering a Left Ventricular Assist Device. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006155.	2.2	5
142	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). American Journal of Cardiovascular Drugs, 2021, 21, 553-561.	2.2	5
143	Use of Outpatient Intravenous Calcitropes for Heart Failure in the United States. Journal of Cardiac Failure, 2021, 27, 1276-1279.	1.7	5
144	Changes over Time in Patient Stated Values and Treatment Preferences Regarding Aggressive Therapies: Insights from the DECIDE-LVAD Trial. Medical Decision Making, 2022, 42, 404-414.	2.4	5

#	Article	IF	CITATIONS
145	Amphetamine-positive urine drug screens in the setting of mexiletine use: A case series. Journal of Heart and Lung Transplantation, 2016, 35, 1045-1048.	0.6	4
146	Managing the Economic Challenges in the Treatment of Heart Failure. Progress in Cardiovascular Diseases, 2018, 61, 476-483.	3.1	4
147	The Effect of Total Cost Information on Consumer Treatment Decisions: An Experimental Survey. Medical Decision Making, 2018, 38, 584-592.	2.4	4
148	<p>Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study</p> . Patient Preference and Adherence, 2020, Volume 14, 2225-2230.	1.8	4
149	Stress and Coping Among Family Caregivers of Patients With a Destination Therapy Left Ventricular Assist Device: A Multicenter Mixed Methods Study. Circulation: Heart Failure, 2021, 14, e008243.	3.9	4
150	Time Spent Engaging in Health Care Among Patients With Left Ventricular Assist Devices. JACC: Heart Failure, 2022, 10, 321-332.	4.1	4
151	Managing the economic challenges in the treatment of heart failure. BMC Cardiovascular Disorders, 2021, 21, 612.	1.7	4
152	Getting a Grip on Frailty: Handgrip Strength in Patient Selection for Left Ventricular Assist Device. Journal of Cardiac Failure, 2014, 20, 316-318.	1.7	3
153	Metaâ€Analysis of Medication Adherence Interventions Among Heart Failure Patients: The Lumpers Make Their Case. Journal of the American Heart Association, 2016, 5, .	3.7	3
154	Peer Review of a Manuscript Submission. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	3
155	Shared Decision-Making for Left Ventricular Assist Devices. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007256.	2.2	3
156	Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation: Heart Failure, 2021, 14, e007759.	3.9	3
157	Did You Forget to Assess Cognition in Your Patient With Heart Failure, and Does It Matter?. Journal of Cardiac Failure, 2021, 27, 295-296.	1.7	3
158	Fulminant Myocarditis Following SARS-CoV-2 Infection. JACC: Case Reports, 2022, 4, 567-575.	0.6	3
159	Caregiver Perspectives on End-of-Life Experiences of Patients With Left Ventricular Assist Devices—Reply. JAMA Internal Medicine, 2016, 176, 1231.	5.1	2
160	Goldilocks Dilemma of Dose Titration in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	3.9	2
161	Behind the Scenes in "The Real World―ofÂHeart Transplantation. Journal of the American College of Cardiology, 2018, 71, 1726-1728.	2.8	2
162	When the VEST Does Not Fit. Circulation: Heart Failure, 2018, 11, e005116.	3.9	2

#	Article	IF	CITATIONS
163	Inclusion of Performance Parameters and Patient Context in the Clinical Practice Guidelines for Heart Failure. Journal of Cardiac Failure, 2021, 27, 190-197.	1.7	2
164	Development of a Decision Aid for Patients and Families Considering Hospice. Journal of Palliative Medicine, 2021, 24, 505-513.	1.1	2
165	Vasomotor sympathetic outflow in the muscle metaboreflex in low birth weight young adults. Integrated Blood Pressure Control, 2015, 8, 37.	1.2	1
166	Exercise-induced cardiac fatigue in low and normal birth weight young black adults. Cardiology in the Young, 2015, 25, 481-484.	0.8	1
167	Quality of Life After Left Ventricular Assist Device Implantation: In a World Full of Data, #Missingness. Journal of Cardiac Failure, 2016, 22, 338-339.	1.7	1
168	Peer Review of a Manuscript Submission. Circulation: Heart Failure, 2017, 10, .	3.9	1
169	Cocaine, HeartÂFailure, and Carvedilol. JACC: Heart Failure, 2019, 7, 779-781.	4.1	1
170	Educate, Engage, Empower. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e006107.	2.2	1
171	Exploring differences between patients who accept, decline, and are deemed ineligible for left ventricular assist device implantation as destination therapy. Journal of Heart and Lung Transplantation, 2020, 39, 721-724.	0.6	1
172	Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). American Journal of Cardiology, 2020, 132, 66-71.	1.6	1
173	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation: Cardiovascular Interventions, 2020, 13, e008274.	3.9	1
174	Development of a measure of decision quality for implantable defibrillators. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 677-684.	1.2	1
175	Acute Myocardial Infarction Cohorts Defined by International Classification of Diseases, Tenth Revision Versus Diagnosis-Related Groups. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006570.	2.2	1
176	Policy and Payment Challenges in the Postpandemic Treatment of Heart Failure: Value-Based Care and Telehealth. Journal of Cardiac Failure, 2022, 28, 835-844.	1.7	1
177	Rationale and study design of a patient-centered intervention to improve health status in chronic heart failure: The Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) randomized trial. , 2016, 51, 1-1.		1
178	Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure. MDM Policy and Practice, 2021, 6, 238146832110416.	0.9	1
179	Health Literacy in Patients Considering a Left Ventricular Assist Device: Findings from the DECIDE-LVAD Trial. Journal of Cardiac Failure, 2022, , .	1.7	1
180	End-Point Selection for Acute Heart Failure Trials. Heart Failure Clinics, 2011, 7, 481-495.	2.1	0

#	Article	IF	CITATIONS
181	Simultaneous Use of Intravenous Fluids and Diuretics in Patients Hospitalized With Heart Failure. JACC: Heart Failure, 2015, 3, 134-135.	4.1	0
182	Predicting in-hospital worsening heart failure at time of admission, but do we really need another heart failure risk model?. American Heart Journal, 2016, 178, 188-189.	2.7	0
183	Gradual Increases in Scheduled and Actual Early Follow-Up After Heart Failure Hospitalization. Circulation: Heart Failure, 2016, 9, .	3.9	0
184	Patient-centered outcomes with next-generation left ventricular assist devices: One small step, not a giant leap. Journal of Heart and Lung Transplantation, 2018, 37, 136-138.	0.6	0
185	Process Improvement in Heart Failure. Heart Failure Clinics, 2020, 16, xvii-xix.	2.1	0
186	What Can We Learn From Norway?. JACC: Heart Failure, 2020, 8, 928-930.	4.1	0
187	Mis-GUIDED—The Importance of Negative Trials of Health Care Delivery and Implementation Science. JAMA Cardiology, 2021, 6, 135.	6.1	0
188	Adding a Rock to a Hard Place. JACC: CardioOncology, 2021, 3, 316-318.	4.0	0
189	Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines – heart failure participating centers. American Heart Journal, 2022, 246, 1-11.	2.7	0